Dr. Anat Galor, MD

Dr. Galor practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Galor's NPI, 1962452813, was assigned on May 11, 2006. Dr. Galor graduated from WashU Medicine in 2002. Dr. Galor holds Florida license ME98291.

Dr. Galor's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Galor's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. The medical group on file is University of Miami Health System. Dmand AI also links Dr. Galor to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Galor practices, 2 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Galor's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Galor is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Galor's licenses on file in 3 states: Florida, Maryland and Ohio.

Dmand AI lists eyelid inflammation and vision problems among the conditions Dr. Galor treats.

CMS data shows 65 Medicare services from Dr. Galor across 2 procedure codes in 2024, all of them office visits, for 38 Medicare patients. Medicare paid $4,854 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 38 Medicare patients who saw Dr. Galor in 2024. The largest group is 65 to 74, with 22 patients. 75% of them have high cholesterol, and 74% have arthritis. Their average risk score is 1.37, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Galor's median patient age at 56, with 61% women.

In 2024, Dr. Galor wrote 78 Medicare Part D claims for 19 patients. 77% of them were for generic drugs. CMS names the drug for 42 of them, across 2 drugs with 11 or more claims each, at $555 in total drug cost. In 2023, CMS named 66 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Galor for performance year 2024, reported as part of a group. Dr. Galor accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Galor as offering telehealth.

Dmand AI links 406 papers to Dr. Galor, published from 2005 to 2025. 2023 was the busiest year, with 32. The most frequent topics are Dry Eye Syndromes, Cornea and Tears. Dr. Galor has published most often in Cornea. Dr. Galor's most frequent co-authors are Carol L. Karp, MD, Roy Clifford Levitt, MD and Sander R. Dubovy, MD.

Dmand AI links Dr. Galor to 4 clinical trials. Conditions studied include Dry Eye Syndromes, Herpes Zoster Ophthalmicus and Neuralgia. University of Miami sponsors the most, 2.

CMS Open Payments shows 188 general payments to Dr. Galor from 33 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 62% of the total. Dompe US, Inc. paid the most, $22,675.

Dmand AI lists 28 awards for Dr. Galor, most recently American Ophthalmology Society in 2018.

Dr. Galor graduated from WashU Medicine in 2002. Dr. Galor is a member of AAO.

Dr. Galor is in network with 12 carriers, including Aetna, Elevance and United Healthcare. PPO plans come from the most carriers, 7. Check the plan with the practice before a visit.